Novasep signs a letter of intent with Pfizer to be part of the global supply chain of PAXLOVID
Lyon, France, 17 January 2022 - Novasep is pleased to announce that it has signed a letter of intent with Pfizer, to be part of the global supply chain for their novel protease inhibitor, PAXLOVID, which targets Covid-19. Novasep, a trusted and experienced partner to Pfizer, will manufacture active pharmaceutical ingredient (API) for the oral protease inhibitor against Covid-19, joining Pfizer’s expanding global manufacturing network of suppliers, which will now span three continents and are projected to make up to 120 million patient packs of protease inhibitor worldwide by the end of 2022.
As agreed by both parties, technical transfer, on-site development and equipment installation activities will begin immediately. Novasep’s Mourenx facility in France is expected to be incorporated into the protease inhibitor against Covid-19 supply chain of Pfizer as early as Q3 2022 with further expansion to other Novasep facilities and significantly increased volumes in 2023.
At this stage, the group is planning to recruit more than 40 additional employees dedicated to this project at the Mourenx site.
Our CEO Dr. Michel Spagnol, comments: “We are honored by this renewed proof of confidence, Pfizer being a long-time customer of Novasep and we are of course proud to contribute to the manufacturing of this medicine which has shown in clinical trials to have a positive impact on hospitalization among at-risk Covid-19 patients. This contract also validates our investment strategy for several years and our focus on small molecules”.
About Novasep
Novasep offers flexible CDMO solutions for small molecule APIs and ADCs to innovators. The business proposes a wide range of flexible cGMP manufacturing assets on multiple sites with an outstanding regulatory track record. Novasep is a world leader in several specialized technologies including hazardous and cryogenic chemistries and industrial scale chromatography. Headquartered in Lyon, Novasep operates five manufacturing and R&D sites in France and Germany which benefit from end-to-end clinical to commercial capabilities. The business has over 1,000 employees globally.
Press Contact
Agnès Catineau/Solène Deguet
+33 7 78 50 95 46
novasep@brunswickgroup.com
2022 01 17_PR Pfizer x Novasep_Paxlovid_EN
Back to our full list of News